Nasdaq
$11.74▼ 0.66%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.59BShares out 3.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 8.24After-hours26.08.25 06:214Ownership#●●●#●●●
AbCellera Biologics Inc.
AbCellera Biologics Inc. insider Michael R. Hayden filed a Form 4 on August 24, 2026, to report changes in beneficial ownership of securities. This filing serves as an official record of insider equity activity and does not involve transactions that directly impact the company's management or financial position.…more
$11.74-0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18Regular26.08.19 03:454Ownership
AbCellera Biologics Inc.
Insider John S. Montalbano of AbCellera Biologics Inc. reported a change in beneficial ownership of securities via Form 4 filed on August 18, 2026. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$11.74-0.66%vs prev closeView filingShare - 8.11After-hours26.08.12 05:59424B5Offering
AbCellera Biologics Inc.
앱셀레라 바이오로직스(AbCellera Biologics Inc.)는 2억 달러 규모의 보통주 및 사전 발행 워런트(pre-funded warrants) 발행을 결정했습니다. 이번 유상증자를 통해 조달된 자금은 회사의 운영 및 임상 개발 등 전반적인 사업 목적에 사용될 예정입니다.…more
$11.74-0.66%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8After-hours26.10.09 05:09#●●●#●●●#●●●
AbCellera Presents Phase 1/2 Data On ABCL635 At TMS 2026 Annual Meeting…more
AbCellera presented clinical data from its Phase 1/2 study of ABCL635 at the TMS 2026 Annual Meeting. As this is an early-stage clinical presentation without definitive regulatory outcomes, the impact remains neutral.…more
$11.74-0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.16After-hours26.09.17 05:08
●●●●●●●● ●●●●● ●●●●●●
AbCellera announced it will present interim Phase 2 clinical data for its vasomotor symptom treatment, ABCL635, at the upcoming 20th World Congress on Menopause. The presentation will detail the efficacy and safety results observed in postmenopausal women.…more
$11.74-0.66%vs prev closeShareBenzinga - 8.25Regular26.08.26 03:38
●●●●●●●● ●●●●● ●●●●●●
AbCellera Biologics stock rose following the FDA approval of a partner's treatment, despite no direct company news. Investors should remain cautious as technical indicators suggest the stock is currently in overbought territory.…more
$11.74-0.66%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report